Query
Find articles
Pick a keyword, optionally a second one to combine it with (and, or, either but not both, or but not), then narrow the articles down by text, source and time range. Keywords update the results right away; filters apply with their button.
Query
How they overlap
Of the articles on each keyword in the last 7 days, with the same text and sources, how many also mention the other. Per lean: the share of its outlets' articles on Moderna that mention Merck.
57.1% of the 7 articles on Moderna also mention Merck, as do 80.0% of the 5 articles on Merck.
- Left-leaning2 of 4 articles
- 50.0%
- Least biased0 of 1 article
- 0.0%
- Right-leaning2 of 2 articles
- 100.0%
Who picked it up when
TIME mentioned it first (Oct 22, 2026, 7:54 PM EDT). Right-leaning outlets followed 8 hours later. No least biased outlet mentioned it.
One row per source with a matching article, from the most left-leaning on top: a dot for each article, on a bar for each stretch of its coverage (a pause of more than 24 hours starts a new one). Hover or tap a dot for the headline, click it to read the article.
Source lean:leftcenterright
Source leans by Media Bias/Fact Check.
Results
4 articles mention Moderna and Merck in the last 7 days (Oct 20 to Oct 26).
| Article | |||
|---|---|---|---|
| The Daily Wire | Personalized Cancer Vaccine Shows Promise In Major TrialThe Daily Wire Pharmaceutical companies Merck and Moderna reported that an experimental personalized mRNA vaccine, given alongside the immunotherapy drug Keytruda, reduced the risk of melanoma recurrence or death by 42% compared with Keytruda alone. The Phase 3 trial included 1,137 patients with Stage IIB-IV melanoma whose tumors had been surgically removed. The findings could bring the drugmakers ... | 0.50 | |
| CNBC | Doctors call Moderna, Merck cancer vaccine data a major advancement — despite Wall Street reactionCNBC Six melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful result for melanoma patients who underwent surgery. | 0.60● | |
| New York Post | First-of-its-kind cancer vaccine helps reduce chances of melanoma patients’ tumors returning: studyNew York Post A first-of-its-kind cancer vaccine is significantly reducing the chances that melanoma patients’ tumors come back, according to results of a major study released Thursday by drugmakers Moderna and Merck. | 0.45 | |
| TIME | A Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42%TIME The treatment is still experimental, but results from Moderna and Merck add scientific support for a vaccine-based approach to treating the cancer. | 0.40 |
Source leans by Media Bias/Fact Check.
Narrow further
Other keywords in the matching articles: the share of them that mention each, with the number of articles. The search icon searches for Moderna and that keyword instead of Merck, keeping the text, sources, source type and time range.
Coverage by source
The share of each source's stories in the last 7 days that match the query, from left to right. Sort the table to reorder the bars.
Source lean:leftcenterright
Source leans by Media Bias/Fact Check.
| TIME | 1.4% | 1 | 70 |
| CNBC | 0.3% | 1 | 328 |
| New York Post | 0.1% | 1 | 900 |
| The Daily Wire | 0.4% | 1 | 238 |
Coverage by lean
The share of stories that match the query, in the last 7 days, averaged over the outlets of each political lean with at least 3 stories. The groups differ in size, so a single outlet weighs more in the smaller ones.
- Left-leaning2 of 15 sources
- 0.1%
- Least biased0 of 8 sources
- 0.0%
- Right-leaning2 of 15 sources
- <0.1%
Lean index −1.4: covered more by left-leaning outlets
Each outlet at its MBFC bias score, from −10 (far left) to +10 (far right), as high as the share of its stories that match the query. The lean index is the average score of the outlets covering it, weighted by that share.
lean indexour sources' average (+0.4)leftcenterright
Bias scores by Media Bias/Fact Check.
Source leans based on ratings by Media Bias/Fact Check.